We explore what allosteric modulators are, their benefits and drawbacks, and which candidates are currently advancing through ...

EM, biochemical, and cell-based assays to examine how Gβγ interacts with and potentiates PLCβ3. The authors present evidence for multiple Gβγ interaction surfaces and argue that Gβγ primarily enhances ...

Newleos Therapeutics, Inc., a clinical-stage biotechnology company developing innovative treatments for neuropsychiatric ...

Neumora Therapeutics (NASDAQ:NMRA) outlined clinical and pipeline updates alongside its fourth-quarter and full-year 2025 ...

Why does ketamine wear off so fast? New research identifies the NOX-1 enzyme as a key target to prolong ketamine’s antidepressant effects for treatment-resistant depression.

Eli Lilly has gone big in the name of neuroscience, paying $6.3 billion in a front-loaded deal for Centessa Pharmaceuticals ...

Track Suven Life Sciences share price today on NSE/BSE with real-time updates. Check stock performance, fundamentals, market cap, shareholding, financial reports, annual & quarterly results, and ...

New data for NMRA-511 supports unsurpassed clinical effect in a pre-specified population comparable to Rexulti and Auvelity pivotal studies ...

Treatment-resistant depression affects a large proportion of people with major depressive disorder, and while ketamine offers ...

New data for NMRA-511 supports unsurpassed clinical effect in a pre-specified population comparable to Rexulti and Auvelity pivotal studies KOASTAL-2 and -3 fully enrolled in the first quarter of 2026 ...

Neumora Therapeutics is downgraded from 'Strong Buy' to 'Hold' following KOASTAL-1's failure in the MDD primary endpoint.

Treatment-resistant depression affects a large proportion of people with major depressive disorder, and while ketamine offers ...